目的 探究腦血栓片聯(lián)合依達拉奉注射液治療急性腦梗死的臨床療效。方法 選取2013年1月-2016年12月于寶豐縣人民醫(yī)院收治的急性腦梗死患者98例為研究對象，所有患者按隨機數(shù)字表法分為對照組和治療組，每組各49例。對照組靜脈滴注依達拉奉注射液，30 mg加入0.9%氯化鈉注射液100 mL中，30 min內(nèi)滴完，2次/d。治療組在對照組治療的基礎(chǔ)上口服腦血栓片，2片/次，3次/d。兩組患者均連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組美國國立衛(wèi)生研究院卒中量表（NIHSS）評分、氧化應(yīng)激因子水平和炎癥因子水平。結(jié)果 治療后，對照組、治療組總有效率分別為77.55%、91.84%，兩組總有效率比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療7、14 d后，兩組NIHSS評分均明顯下降（P<0.05），同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組NIHSS評分顯著低于同期對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療7、14 d后，兩組血清丙二醛（MDA）水平明顯降低，一氧化氮（NO）、超氧化物歧化酶（SOD）水平明顯升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組血清氧化應(yīng)激因子水平明顯優(yōu)于同期對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療7、14 d后，兩組血清腫瘤壞死因子（TNF-α）、白介素（IL）-6、IL-10、超敏C反應(yīng)蛋白（hs-CRP）水平明顯降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組炎癥因子水平均明顯低于同期對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 腦血栓片聯(lián)合依達拉奉注射液治療急性腦梗死患者，能有效改善機體內(nèi)炎癥反應(yīng)和氧化應(yīng)激水平，促進神經(jīng)功能恢復(fù)，且安全性良好，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the effect of Naoxueshuan Tablets combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients (98 cases) with acute cerebral infarction in People's Hospital of Baofeng from January 2013 to December 2016 were randomly divided into control group and treatment group, and each group had 49 cases. Patients in the control group were iv administered with Edaravone Injection, 30 mg Edaravone Injection added into 100 mL 0.9% NaCl injection, twice daily. Patients in the treatment group were po administered with Naoxueshuan Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and NIHSS scores, serum levels of oxidative stress factors, and serum levels of inflammatory factors in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 77.55% and 91.84%, respectively, and there were no differences between two groups. After treatment for 7 and 14 d, NIHSS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And NIHSS scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment for 7 and 14 d, MDA levels in two groups were significantly decreased, but NO and SOD levels were significantly increased, and there were differences in the same group (P<0.05). And serum levels of oxidative stress factors in the treatment group were significantly better than those in the control group in the same period, with significant difference between two groups (P<0.05). After treatment for 7 and 14 d, serum levels of TNF-α, IL-6, hs-CRP in two groups were significantly decreased, and there were differences in the same group (P<0.05). And serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group in the same period, with significant difference between two groups (P<0.05). Conclusion Naoxueshuan Tablets combined with Edaravone Injection has good efficacy in treatment of acute cerebral infarction, and can effectively reduce the level of oxidative stress and inflammatory response, which is conducive to nerve recovery, which has a certain clinical application value.